Title : One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry.

Pub. Date : 2020 Jun

PMID : 31912949






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSIONS: In this prospective, observational and current clinical practice ACS registry, the use of novel oral P2Y12 inhibitors was associated with a reduction in adverse events compared with clopidogrel in patients with ACS. clopidogrel purinergic receptor P2Y12 Homo sapiens
2 However, clopidogrel remained the most common P2Y12 inhibitor employed for ACS, especially in older and high risk population. clopidogrel purinergic receptor P2Y12 Homo sapiens